Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
$6.43
$0.04(1.15%)
At close: 4:00 PM EST
$6.43
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.89 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)2.88M
Market Cap
$1.31B
Enterprise Value$678.21M
Total Cash (Recent Filing)$124.39M
Total Debt (Recent Filing)$29.83M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 26, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding203,467,850
10 Day Avg. Volume4,375,251
30 Day Avg. Volume2,878,193
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.55
Price to Sales (P/S)0.00
P/FCF Ratio-6.83
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-498.69
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$9.20Price Target Upside43.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PotentialMOLBREEVI is anticipated to achieve blockbuster status in the US, contingent on its approval.
Product Approval And Market GrowthThe approval of MOLBREEVI, along with the growing availability of a simple diagnostic test, is expected to drive earlier diagnosis and market growth.
Regulatory And Manufacturing StrategyThe decision to proceed with Fujifilm rather than GEMA Biotech, together with substantial data generated from the Process Performance Qualification campaigns at Fujifilm and the FDA’s alignment on both the analytical comparability package and the CMC data to be included in the BLA, meaningfully de-risks the filling process.
Bears Say
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.31B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 26, 2026 which is in 97 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.132 by -$0.008.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.12.
How many shares outstanding does Savara have?
Savara has 203,467,850 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.132. Following the earnings report the stock price went up 3.398%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (43.08% Upside)
$9.20 (43.08% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.23%
12-Months-Change
Fundamentals
Return on Equity
-78.74%
Trailing 12-Months
Asset Growth
-40.99%
Trailing 12-Months
Company Description
Savara
Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases. The company's primary therapeutic area includes conditions such as pulmonary alveolar proteinosis (PAP) and idiopathic pulmonary fibrosis (IPF). Savara's lead product candidate is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is currently in clinical development for the treatment of PAP.
SVRA Stock 12 Month Forecast
Average Price Target
$9.20
▲(43.08% Upside)
Technical Analysis
Ownership Overview
12.31% Insiders
6.76% Mutual Funds
58.43% Other Institutional Investors
14.98% Public Companies and
Individual Investors